Skip to main content
GNI Group Ltd. logo

GNI Group Ltd. — Investor Relations & Filings

Ticker · 2160 ISIN · JP3386370005 LEI · 5299005KSTCN0WVJMQ52 T Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2024-03-28 Governance Information
Country JP Japan
Listing T 2160

About GNI Group Ltd.

https://www.gnipharma.com/

GNI Group Ltd. is a vertically integrated, multinational biopharmaceutical company engaged in the full spectrum of drug development, from research and clinical trials to manufacturing, sales, and marketing. The company's portfolio includes pharmaceutical drugs, traditional Chinese medicines, and medical devices. Its research and development efforts are primarily focused on creating therapies for diseases such as cancer and inflammation, with a particular emphasis on conditions prevalent in Asian populations. The group utilizes genetic information and analysis technology to advance its drug discovery programs.

Recent filings

Filing Released Lang Actions
内部統制報告書－第23期(2023/01/01－2023/12/31)
Governance Information Classification · 100% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly states its basis under Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act (金融商品取引法第24条の４の４第１項). It details the scope, criteria (based on the Financial Reporting Internal Control Evaluation and Audit Standards), and the conclusion that internal controls over financial reporting are effective as of the end of the fiscal year (December 31, 2023). This structure and content definitively classify it as a formal internal control report related to financial reporting, which aligns with the scope of an Annual Report (10-K) or a standalone Audit/Control Report. Since the definition for 'Audit Report / Information' (AR) includes reports on internal or regulatory stress tests, and this is a specific, required internal control report, AR is the most appropriate classification among the provided options, as 10-K usually refers to the comprehensive annual filing which includes this section, but this document appears to be the standalone control report itself. Given the specific nature of the content (Internal Control Report), it fits best under AR, which covers standalone audit/control reports.
2024-03-28 Japanese
確認書
Regulatory Filings Classification · 95% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act, Article 24-4-2, Paragraph 1. It serves as an officer certification confirming the accuracy of the company's Annual Securities Report (有価証券報告書). According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type, as they do not contain the actual financial statements themselves. FY 2023
2024-03-28 Japanese
有価証券報告書－第23期(2023/01/01－2023/12/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains comprehensive financial data, including consolidated and non-consolidated financial indicators for the fiscal year ending December 31, 2023, and is filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It is a full annual report, not an announcement or a summary. FY 2023
2024-03-28 Japanese
臨時報告書
Legal Proceedings Report Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director on January 18, 2024. The filing reason explicitly states that an event significantly impacting the company's financial condition, operating results, and cash flow has occurred, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details a specific corporate action (debt repayment via stock transfer) that has a material financial impact (approx. 1.1 billion JPY in interest income and 1.7 billion JPY in foreign exchange gain). This structure—a formal, timely disclosure of a material, non-periodic event under Japanese securities law—is characteristic of a Japanese Extraordinary Report, which aligns best with the general 'Regulatory Filings' category (RNS) as there is no specific code for a Japanese 'Timely Disclosure' document that isn't a standard periodic report (like 10-K or IR). Given the nature of the disclosure (material event reporting), RNS is the most appropriate fit among the provided codes, as it serves as a general regulatory announcement fallback.
2024-01-18 Japanese
訂正臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled '訂正臨時報告書' (Corrected Extraordinary Report) and is filed with the Kanto Local Finance Bureau ('関東財務局長'). It explicitly states it is submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and related regulations, which mandates filing an Extraordinary Report ('臨時報告書') when a significant event affecting financial condition, operating results, or cash flows occurs. The content details a specific financial event (conversion of preferred stock into common stock leading to recognition of other income). This structure and purpose align perfectly with a significant, non-periodic disclosure required under Japanese regulations, which is best categorized as a general Regulatory Filing (RNS) or potentially an extraordinary report if a specific code existed, but given the provided list, RNS serves as the best fit for mandatory, non-standard regulatory disclosures that aren't 10-K, AR, or ER/IR. Since it is a formal, mandatory filing detailing a significant event, RNS is the most appropriate general regulatory category.
2023-12-08 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is filed with the Kanto Local Finance Bureau (関東財務局長) on December 7, 2023. The content explicitly states that the filing is made pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, due to a significant event affecting the company's financial condition, operating results, and cash flow. This structure and legal basis strongly indicate a mandatory, unscheduled regulatory filing in Japan that is not a standard periodic report (like 10-K or IR). Since it is a mandatory, unscheduled disclosure of a significant event (asset transfer/stock conversion resulting in a large gain), and it doesn't fit perfectly into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general category for miscellaneous, mandatory regulatory disclosures that don't fit elsewhere is 'Regulatory Filings' (RNS). The document length is very short (1045 chars), suggesting it is the announcement itself, not the detailed underlying report.
2023-12-07 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.